Oncology and Ophthalmology Biosimilars Achieve 81% Market Share in Latest Samsung Bioepis Report
核心洞察
Oncology, ophthalmology, and pegfilgrastim biosimilars have demonstrated remarkable success, capturing 81% market share within 5 years of launch according to Samsung Bioepis (搜索)' Q1 2025 report.
Adalimumab biosimilars have disrupted the market with up to 86% lower pricing than Humira, though market share remains at 23% as of November 2024.
The biosimilar landscape shows varying penetration rates, with trastuzumab, bevacizumab, and rituximab biosimilars maintaining strong market positions and significant price discounts ranging from 49% to 66%.
The latest Samsung Bioepis (搜索) Q1 2025 Biosimilar Market Report reveals significant market penetration for oncology, ophthalmology, and pegfilgrastim biosimilars, which have collectively achieved an average market share of 81% within five years of launch. This remarkable growth stands in stark contrast to other therapeutic areas, where biosimilars have shown more modest gains.
Strong Performance in Oncology and Supportive Care
Biosimilar uptake has been particularly impressive in the oncology sector, with individual products gaining an average of 53% market share following their initial launch. The market has responded positively to competitive pricing, with oncology biosimilars offering substantial discounts. Trastuzumab biosimilars now show average savings of 52%, bevacizumab biosimilars 49%, and rituximab biosimilars 66% compared to reference products.
Market penetration remains robust across key oncology products, with biosimilars commanding 86% of the trastuzumab market, 90% of the bevacizumab market, and 76% of the rituximab market. The pegfilgrastim biosimilar segment maintains a strong 85% market share.
Adalimumab Market Dynamics
The adalimumab biosimilar landscape has emerged as a particularly competitive space, though market share reached only 23% by November 2024. Notable entrants like Hadlima, Yusimry, and Simlandi (搜索) have introduced aggressive pricing strategies, offering WAC prices 85-86% lower than Humira. Manufacturers have adopted various approaches, including dual pricing options and private label strategies, to gain market share.
Pricing Trends and Market Evolution
The Q1 2025 report highlights interesting pricing dynamics across different therapeutic areas. Trastuzumab biosimilars showed an average ASP of $1,468, marking a 7% increase from the previous quarter. Conversely, bevacizumab biosimilars experienced a slight decrease to $1,399, while rituximab biosimilars declined to $1,247.
Emerging Biosimilar Markets
Some therapeutic areas have shown slower adoption rates. Immunology, filgrastim, epoetin alfa, and insulin glargine biosimilars have achieved only 26% market share after five years. The tocilizumab biosimilar market, being relatively new, is still developing, with an ASP of $1,840 in Q1 2025.
Future Outlook
Thomas Newcomer, vice president and head of market access at Samsung Bioepis (搜索), anticipates significant market developments with upcoming biosimilar launches for aflibercept, ustekinumab, and denosumab. These new entrants are expected to further shape the competitive landscape and potentially impact pricing dynamics across therapeutic areas.
The varying success rates across different biosimilar categories highlight the complex interplay of factors affecting market adoption, including pricing strategies, healthcare provider preferences, and payer policies. As the biosimilar market continues to mature, these patterns of adoption and pricing will likely influence future market entry strategies and healthcare cost management efforts.